Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 215663, held by Ajanta Pharma Ltd. Topiramate.
As of Nov 15, 2026, ANDA 215663 (Topiramate), held by Ajanta Pharma Ltd, was first approved by FDA on Aug 15, 2023, with 3 approved supplements and 0 published complete response letters.
Topiramate extended-release capsules are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older; adjunctive therapy for the treatment of partial-onset, primary generalized tonic-clonic seizures, or seizures associated with Lennox- Gastaut syndrome (LGS) in patients 6 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate extended-release capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 15, 2023 | Original application | Approved | None posted |
| Topiramate25MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate50MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate100MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate200MG · capsule, extended release;oral | Topiramate | Rx |
| Oct 5, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 23, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 30, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 15, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters